


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					Docket No. 03654.0255.I APPLICANT Erwin SI et al.		
AUG 23 2000 U.S. PATENT & TRADEMARK OFFICE RECEIVED					APPLICATION NO. 09/523,102 FILING DATE March 10, 2000 GROUP 1651 TECH CENTER 1600 FILING DATE AUG 29 2000		
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS	REF. NO.	DOCUMENT NUMBER	GRANT DATE	NAME	CLASS	SUB-CLASS	FILING DATE
BTD	AA1	2,798,053	07/1957	Brown			
	AB1	4,136,250	01/1979	Mueller et al.			
	AC1	4,192,827	03/1980	Mueller et al.			
	AD1	4,548,990	10/1985	Mueller et al.			
	AE1	4,816,456	03/1989	Summers			
	AF1	5,188,826	02/1993	Chandrasekaran et al.			
	AG1	5,192,535	03/1993	Davis et al.			
	AH1	5,260,059	11/1993	Acott et al.			
	AI1	5,240,958	08/1993	Campion et al.			
	AJ1	5,684,152	11/1997	Ponpipom et al.			
BTD	AK1	5,691,382	11/1997	Crimmin et al.			
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS	REF. NO.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
BTD	AL1	WO 97/18835	05/1997	PCT			Yes No
	AM1	WO 97/43245	11/1997	PCT			Yes No
	AN1	WO 97/43247	11/1997	PCT			Yes No
	AO1	WO 98/07697	02/1998	PCT			Yes No
BTD	AP1	WO 98/09940	03/1998	PCT			Yes No
EXAMINER INITIALS	REF. NO.		OTHER (Including Author, Title, Date, Pertinent Pages, etc.)				
BTD	AR	1	ARVO Abstract Book, Annual Meeting Fort Lauderdale, Florida May 9-14, 1999, IOVS , March 1999, Vol. 40, No. 4, p. S231.				
	AS	1	Arup Das, et al., <i>Human Diabetic Neovascular Membranes Contain High Levels of Urokinase and Metalloproteinase Enzymes</i> , IOVS, March 1999, Vol. 40, No. 3, 809-813.				
BTD	AT	1	Arup Das, et al., <i>Retinal Neovascularization Is Suppressed With a Matrix Metalloproteinase Inhibitor</i> , Archive of Ophthalmology, Vol. 117, No. 4, April 1999, 498-503.				
EXAMINER					DATE CONSIDERED		
							5/8
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 03654.0255.I

APPLICATION NO. 09/523,102

APPLICANT Erwin SI et al.

FILING DATE March 10, 2000

GROUP 1651

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	GRANT DATE	NAME	CLASS	SUB-CLASS	FILING DATE
Bt	AA2	5,696,082	12/1997	Crimmin et al.			
	AB2	5,700,838	12/1997	Dickens et al.			
	AC2	5,763,621	06/1998	Beckett et al.			
	AD2	5,801,156	09/1998	Robinson et al.			
	AE2	5,861,436	01/1999	Beckett et al.			
	AF2	5,861,510	01/1999	Piscopio et al.			
	AG2	5,863,949	01/1999	Robinson et al.			
	AH2	5,866,717	02/1999	Beckett et al.			
	AI2	5,872,152	02/1999	Brown et al.			
	AJ2	5,902,791	05/1999	Beckett et al.			
Bt	AK2	5,917,090	06/1999	Huxley et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
Bt	AL2	WO 98/12211	03/1998	PCT			Yes No
	AM2	WO 98/16520	04/1998	PCT			Yes No
	AN2	WO 98/33768	08/1998	PCT			Yes No
	AO2	WO 99/19296	04/1999	PCT			<input checked="" type="checkbox"/> Yes No
Bt	AP2	EP 0 895 988 A1	2/1999	Europe			Yes No

EXAMINER INITIALS	REF. NO.	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)		
Bt	AR 2	Joseph Frucht-Pery, MD, et al., <i>Topical Indomethacin Solution Versus Dexamethasone Solution for Treatment of Inflamed Pterygium and Pinguecula: A Prospective Randomized Clinical Study</i> , American Journal of Ophthalmology, February 1999, Vol. 127, 148-152.		
	AS 2	G. A. Lutty, et al., <i>Nonperfusion of retina and choroid in transgenic mouse models of sickle cell disease</i> , Current Eye Research, Vol. 17, No. 4, April 1998, 438-444.		
Bt	AT 2	N. N. Osborne, et al., <i>Topically Applied Betaxolol Attenuates NMDA-induced Toxicity to Ganglion Cells and the Effects of Ischaemia to the Retina</i> , Exp. Eye Res. (1999) 69, 331-342.		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 03654.0255.I	APPLICATION NO. 09/523,102
		APPLICANT Erwin SI et al.	
		FILING DATE March 10, 2000	GROUP 1651

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	GRANT DATE	NAME	CLASS	SUB-CLASS	FILING DATE
BTD	AA3 5,925,637	07/1999	VanZandt et al.			
	AB3 5,929,097	07/1999	Levin et al.			
	AC3 5,932,572	08/1999	Dean et al.			
BTD	AD3 5,932,695	08/1999	Floyd et al.			
AE3						
AF3						
AG3						
AH3						
AI3						
AJ3						
AK3						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
BTD	AL3 EP 0 930 067 A2	07/1999	Europe			Yes No
	AM3					Yes No
	AN3					Yes No
	AO3					Yes No
	AP3					Yes No

EXAMINER INITIALS	REF. NO.	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)				
BTD	AR 3	Gholam A. Peyman, <i>Vitreoretinal Diseases: Pathological Aspects and Therapeutic Strategies</i> , Ocular Therapeutics and Drug Delivery A Multi-Disciplinary Approach, 265-266.				
	AS 3	Lutz E. Pillunat, et al., <i>Effect of topical dorzolamide on optic nerve head blood flow</i> , <i>Craefes Arch Clin Exp Ophthalmol</i> (1999) 237: 495-500.				
BTD	AT 3	Maria Emanuel Ryan, et al., <i>MMP-Mediated Events in Diabetes</i> , <i>Annals of the New York Academy of Sciences Volume 878 Inhibition of Matrix Metalloproteinases Therapeutic Applications</i> , 1999, 311-334.				

EXAMINER	DATE CONSIDERED
	5/8

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

				ATTY. DOCKET NO. 03654.0255.1		APPLICATION NO. 09/523,102	
FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		AUG 23 2000		APPLICANT Erwin SI et al.			
				FILING DATE March 10, 2000		GROUP 1651	
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NUMBER	GRANT DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA4							AUG 28 2000 TECH 1600/2900
AB4							
AC4							
AD4							
AE4							
AF4							
AG4							
AH4							
AI4							
AJ4							
AK4							
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL4							Yes No
AM4							Yes No
AN4							Yes No
AO4							Yes No
AP4							Yes No
EXAMINER INITIALS	REF. NO.	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)					
B70	AR 4	Masamitsu Shimazawa, et al., <i>Effect of Lomerizine, a New Ca²⁺ Channel Blocker, on the Microcirculation in the Optic Nerve Head in Conscious Rabbits: a Study Using a Laser Speckle Technique</i> , Exp. Eye Res. (1999) 69, 185-193.					
	AS 4	Sebastian Wolf, et al., <i>Acute effect of metipranolol on the retinal circulation</i> , British Journal of Ophthalmology 1998; 82: 892-896.					
B80	AT 4	Edward J. Zabawski, Jr., DO, et al., <i>Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects</i> , Journal of the American Academy of Dermatology 1998; 39: 741-5.					
EXAMINER				DATE CONSIDERED 5/8			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							